HSPPC-96 vaccine in metastatic melanoma patients: From the state of the art to a possible future

Research output: Contribution to journalArticlepeer-review

Abstract

Heat-shock proteins are highly conserved, stress-induced proteins with chaperone function for trafficking and delivering peptides within the different compartments of the cell. Tumor-derived heat-shock protein-peptide complexes (HSPPCs) can be used for vaccination against malignancies. In particular, the HSPPC-96-based vaccine vitespen (formerly Oncophage®) is the first autologous cancer vaccine made from individual patients' tumors that has shown encouraging results in clinical trials. In Phase I and II clinical trials, this vaccine has shown activity on different malignancies, such as gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin's lymphoma and chronic myelogenous leukemia. In Phase III clinical trials in melanoma and kidney cancer, it demonstrated an excellent safety profile with almost no toxicity. Heat-shock protein-based vaccines can be considered as a novel therapeutic approach with a promising role in cancer management.

Original languageEnglish
Pages (from-to)1513-1526
Number of pages14
JournalExpert Review of Vaccines
Volume8
Issue number11
DOIs
Publication statusPublished - Nov 2009

Keywords

  • Heat-shock protein
  • HSP
  • HSPPC
  • Metastatic melanoma
  • Oncophage®
  • Vaccine
  • Vitespen

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'HSPPC-96 vaccine in metastatic melanoma patients: From the state of the art to a possible future'. Together they form a unique fingerprint.

Cite this